IPSC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IP

Mkt Cap

$249.0M

Volume

648.20K

Next Earnings

November 12th

Loading chart

IP

IPSCCentury Therapeutics, Inc. Common Stock

IPSC

Pay with—

Available Balance0.00

IP

Mkt Cap

$271.6M

Volume

648.20K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsightThe cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.GlobeNewswire Inc. · Jun 22, 2026

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsightThe lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.GlobeNewswire Inc. · Jun 10, 2026

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyGT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.Benzinga · Jun 2, 2026

Century Therapeutics Reports First Quarter Financial Results and Business UpdatesCentury Therapeutics reported Q1 2026 financial results with $217.0 million in cash runway extending into 1Q 2029. The company's lead program CNTY-813, an iPSC-derived islet therapy for type 1 diabetes, remains on track for IND submission in 4Q 2026 with initial clinical data expected in 2H 2027. CNTY-308, a CD19-targeted CAR-iT cell therapy, is progressing toward clinical initiation in 2026. R&D expenses decreased to $17.1 million from $26.6 million year-over-year due to personnel reductions and lower clinical trial spending.GlobeNewswire Inc. · May 13, 2026

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightThe iPSC-derived NK cells clinical trial pipeline is experiencing significant momentum with 12+ companies developing 15+ pipeline therapies. Key players including Century Therapeutics, Fate Therapeutics, Cartherics, and others are advancing promising candidates like CNTY-101, FT522, and CTH-401 across various clinical stages. Recent developments include Century's CNTY-101 continuation in Phase I/II trials and Fate's positive initial data from FT522 in relapsed/refractory B-cell lymphoma, positioning iPSC-derived NK cells as a cornerstone of next-generation cancer immunotherapy.GlobeNewswire Inc. · Feb 16, 2026

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of DirectorsCentury Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.GlobeNewswire Inc. · Dec 9, 2025

Century Therapeutics Announces New Beta Islet Program for Type 1 DiabetesCentury Therapeutics has developed an innovative iPSC-derived beta islet therapy (CNTY-813) for Type 1 Diabetes, engineered with Allo-Evasion™ 5.0 technology to potentially provide durable glucose control without chronic immunosuppression. Preclinical data shows promising results in glucose normalization and immune protection.GlobeNewswire Inc. · Nov 13, 2025

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceCentury Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, with an on-demand webcast available and investor meetings scheduled.GlobeNewswire Inc. · Aug 22, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the DomainThe CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.GlobeNewswire Inc. · Mar 5, 2025

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion LeadersCentury Therapeutics has entered into an agreement for an investigator-initiated Phase 1/2 trial of its CNTY-101 cell therapy in patients with B-cell mediated autoimmune diseases. The trial will be led by renowned experts and aims to evaluate the safety, efficacy, and translational data of CNTY-101 in various autoimmune conditions.GlobeNewswire Inc. · Jan 21, 2025

to start trading

IP

IPSCCentury Therapeutics, Inc. Common Stock

IPSC

Pay with—

Available Balance0.00

Your PositionYou don't own any IPSC yet.

Related Tickers

Earnings